Clinical Trial Update: Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial update for Alicaforsen (ISIS 2302) in active Crohn's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Alicaforsen (ISIS 2302) (allicaforsen)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED